A Cost-Effectiveness Analysis of Secukinumab 300 Mg Vs Current Therapies for The Treatment of Moderate to Severe Plaque Psoriasis In Italy

A D'Ausilio; A Aiello; F Daniel; Christopher Graham; A Roccia; M Toumi

doi:doi:10.1016/j.jval.2015.09.574

RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Accept

A Cost-Effectiveness Analysis of Secukinumab 300 Mg Vs Current Therapies for The Treatment of Moderate to Severe Plaque Psoriasis In Italy

D'Ausilio, A., Aiello, A., Daniel, F., Graham, C., Roccia, A., & Toumi, M. (2015). A Cost-Effectiveness Analysis of Secukinumab 300 Mg Vs Current Therapies for The Treatment of Moderate to Severe Plaque Psoriasis In Italy. Value in Health, 18(7), A424. https://doi.org/10.1016/j.jval.2015.09.574

Copy citation

Recent Publications

Article

Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults

Article

Development of a novel shared decision making aid for primary immunodeficiency diseases

Article

Community overdose surveillance

Article

A Cost-Effectiveness Analysis of Secukinumab 300 Mg Vs Current Therapies for The Treatment of Moderate to Severe Plaque Psoriasis In Italy

Publications Info

Recent Publications

Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults

Development of a novel shared decision making aid for primary immunodeficiency diseases

Community overdose surveillance

Epigenetic biomarkers for smoking cessation

Partner With Us

Site